Abstract
Psoriasis is T lymphocyte mediated chronic autoimmune disease, with the prevalence rates ranging between 2 and 3 % in European countries. The choice of the therapeutic strategy should be based on the etiopathogenesis, clinical classification and identification of inducing factors.
Therapeutic methods include topical drugs, systemic drugs and phototherapy. Among topical antipsoriatics, corticosteroids, tazarotene, ditranol, vitamin D analogues and various adjuvants (coal tar, emollients, salicylic acid, etc.) are recommended.
More serious forms of psoriasis are treated with systemic ciclosporin A, etretinate, acitretin and methotrexate. An effective alternative in most serious cases of atopic dermatitis are biological drugs: infliximab, etanercept and efalizumab.